Caribou Biosciences IncNASDAQ:CRBU
- LAST PRICE3.8500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.8100/ 3
- Ask / Lots4.2500/ 3
- Open / Previous Close0.0000 / 3.8500
- Day Range---
- 52 Week Range
- Volume6,725
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRBU |
|---|---|---|
| 09:32 ET | 6716 | 3.99 |
| 09:34 ET | 5125 | 3.96 |
| 09:36 ET | 132 | 3.96 |
| 09:38 ET | 1982 | 3.9404 |
| 09:41 ET | 7138 | 3.91 |
| 09:43 ET | 4601 | 3.935 |
| 09:45 ET | 8877 | 3.94 |
| 09:48 ET | 1116 | 3.9093 |
| 09:50 ET | 2250 | 3.905 |
| 09:52 ET | 1747 | 3.915 |
| 09:54 ET | 19787 | 3.93 |
| 09:56 ET | 8800 | 3.93 |
| 09:57 ET | 600 | 3.93 |
| 09:59 ET | 7434 | 3.9175 |
| 10:03 ET | 4200 | 3.925 |
| 10:06 ET | 5676 | 3.915 |
| 10:08 ET | 2147 | 3.935 |
| 10:10 ET | 700 | 3.92 |
| 10:12 ET | 1746 | 3.93 |
| 10:14 ET | 499 | 3.935 |
| 10:15 ET | 3176 | 3.925 |
| 10:17 ET | 250 | 3.925 |
| 10:19 ET | 1450 | 3.9203 |
| 10:21 ET | 1891 | 3.93 |
| 10:24 ET | 1000 | 3.925 |
| 10:26 ET | 3300 | 3.91 |
| 10:28 ET | 600 | 3.905 |
| 10:30 ET | 13207 | 3.9 |
| 10:32 ET | 1750 | 3.895 |
| 10:33 ET | 500 | 3.89 |
| 10:35 ET | 3864 | 3.899 |
| 10:37 ET | 78036 | 3.885 |
| 10:39 ET | 2029 | 3.88 |
| 10:42 ET | 2162 | 3.865 |
| 10:44 ET | 1700 | 3.86 |
| 10:46 ET | 2126 | 3.855 |
| 10:48 ET | 3418 | 3.86 |
| 10:50 ET | 500 | 3.85 |
| 10:51 ET | 17109 | 3.84 |
| 10:53 ET | 1209 | 3.8497 |
| 10:55 ET | 4199 | 3.85 |
| 10:57 ET | 7280 | 3.865 |
| 11:00 ET | 1200 | 3.85 |
| 11:02 ET | 2900 | 3.855 |
| 11:04 ET | 1800 | 3.845 |
| 11:06 ET | 700 | 3.845 |
| 11:08 ET | 3580 | 3.84 |
| 11:09 ET | 700 | 3.845 |
| 11:11 ET | 3099 | 3.845 |
| 11:13 ET | 4660 | 3.85 |
| 11:15 ET | 1900 | 3.84 |
| 11:18 ET | 300 | 3.845 |
| 11:20 ET | 1400 | 3.845 |
| 11:22 ET | 3636 | 3.85 |
| 11:26 ET | 8120 | 3.86 |
| 11:27 ET | 4409 | 3.85 |
| 11:31 ET | 3005 | 3.855 |
| 11:36 ET | 375 | 3.85 |
| 11:38 ET | 780 | 3.859 |
| 11:40 ET | 250 | 3.859 |
| 11:42 ET | 5912 | 3.835 |
| 11:44 ET | 7097 | 3.825 |
| 11:45 ET | 17446 | 3.82 |
| 11:47 ET | 900 | 3.81 |
| 11:49 ET | 13625 | 3.815 |
| 11:51 ET | 17742 | 3.82 |
| 11:54 ET | 6680 | 3.81 |
| 11:56 ET | 6100 | 3.8 |
| 11:58 ET | 3822 | 3.804 |
| 12:00 ET | 500 | 3.8 |
| 12:02 ET | 5652 | 3.815 |
| 12:03 ET | 1251 | 3.815 |
| 12:07 ET | 2530 | 3.8099 |
| 12:09 ET | 500 | 3.805 |
| 12:12 ET | 1709 | 3.805 |
| 12:14 ET | 3853 | 3.815 |
| 12:18 ET | 6540 | 3.835 |
| 12:20 ET | 1448 | 3.83 |
| 12:21 ET | 1900 | 3.835 |
| 12:23 ET | 5355 | 3.825 |
| 12:27 ET | 600 | 3.82 |
| 12:30 ET | 100 | 3.825 |
| 12:32 ET | 8023 | 3.824 |
| 12:34 ET | 1240 | 3.825 |
| 12:36 ET | 940 | 3.825 |
| 12:38 ET | 200 | 3.825 |
| 12:39 ET | 200 | 3.825 |
| 12:41 ET | 1400 | 3.825 |
| 12:43 ET | 100 | 3.825 |
| 12:45 ET | 1017 | 3.825 |
| 12:48 ET | 700 | 3.82 |
| 12:50 ET | 100 | 3.8299 |
| 12:52 ET | 400 | 3.83 |
| 12:54 ET | 5522 | 3.845 |
| 12:56 ET | 200 | 3.845 |
| 12:59 ET | 219 | 3.84 |
| 01:01 ET | 3913 | 3.86 |
| 01:03 ET | 1825 | 3.855 |
| 01:06 ET | 2540 | 3.86 |
| 01:08 ET | 1100 | 3.865 |
| 01:10 ET | 800 | 3.865 |
| 01:14 ET | 100 | 3.865 |
| 01:15 ET | 250 | 3.8656 |
| 01:19 ET | 100 | 3.8601 |
| 01:30 ET | 210 | 3.865 |
| 01:32 ET | 100 | 3.87 |
| 01:33 ET | 100 | 3.86 |
| 01:35 ET | 100 | 3.865 |
| 01:37 ET | 200 | 3.865 |
| 01:39 ET | 1672 | 3.875 |
| 01:42 ET | 128 | 3.88 |
| 01:48 ET | 1128 | 3.875 |
| 01:50 ET | 1179 | 3.875 |
| 01:51 ET | 600 | 3.88 |
| 01:55 ET | 100 | 3.88 |
| 01:57 ET | 1300 | 3.875 |
| 02:00 ET | 800 | 3.875 |
| 02:02 ET | 8641 | 3.865 |
| 02:04 ET | 495 | 3.86 |
| 02:06 ET | 4774 | 3.855 |
| 02:08 ET | 1500 | 3.855 |
| 02:09 ET | 100 | 3.855 |
| 02:11 ET | 500 | 3.8539 |
| 02:13 ET | 7193 | 3.845 |
| 02:15 ET | 400 | 3.835 |
| 02:18 ET | 625 | 3.83 |
| 02:22 ET | 428 | 3.835 |
| 02:24 ET | 300 | 3.83 |
| 02:26 ET | 5497 | 3.825 |
| 02:27 ET | 8933 | 3.84 |
| 02:29 ET | 241 | 3.84 |
| 02:31 ET | 4212 | 3.845 |
| 02:33 ET | 600 | 3.845 |
| 02:36 ET | 1225 | 3.85 |
| 02:38 ET | 2282 | 3.8499 |
| 02:40 ET | 5911 | 3.855 |
| 02:42 ET | 3717 | 3.855 |
| 02:44 ET | 497 | 3.845 |
| 02:45 ET | 1277 | 3.845 |
| 02:47 ET | 433 | 3.8489 |
| 02:49 ET | 3154 | 3.8499 |
| 02:51 ET | 4447 | 3.835 |
| 02:56 ET | 200 | 3.835 |
| 02:58 ET | 7055 | 3.83 |
| 03:00 ET | 1267 | 3.835 |
| 03:02 ET | 1100 | 3.83 |
| 03:03 ET | 6311 | 3.825 |
| 03:05 ET | 1341 | 3.82 |
| 03:07 ET | 1927 | 3.825 |
| 03:09 ET | 5800 | 3.825 |
| 03:12 ET | 5903 | 3.82 |
| 03:14 ET | 5478 | 3.8335 |
| 03:16 ET | 107 | 3.83 |
| 03:18 ET | 355 | 3.835 |
| 03:20 ET | 13704 | 3.835 |
| 03:21 ET | 300 | 3.835 |
| 03:23 ET | 14114 | 3.83 |
| 03:25 ET | 600 | 3.83 |
| 03:27 ET | 1010 | 3.835 |
| 03:30 ET | 4964 | 3.82 |
| 03:32 ET | 700 | 3.825 |
| 03:34 ET | 4440 | 3.84 |
| 03:36 ET | 325 | 3.835 |
| 03:38 ET | 200 | 3.8388 |
| 03:39 ET | 988 | 3.84 |
| 03:41 ET | 12227 | 3.845 |
| 03:43 ET | 2900 | 3.8499 |
| 03:45 ET | 14351 | 3.855 |
| 03:48 ET | 3300 | 3.86 |
| 03:50 ET | 3270 | 3.85 |
| 03:52 ET | 16794 | 3.845 |
| 03:54 ET | 100 | 3.845 |
| 03:56 ET | 25093 | 3.865 |
| 03:57 ET | 32939 | 3.855 |
| 03:59 ET | 20229 | 3.85 |
Yesterday
Apr 15, 2024
Apr 4, 2024
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus, from 4:00PM ET on Thursday Apr 04, 2024 by Dow Jones
4:00PM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Caribou Biosciences Inc | 347.7M | -2.7x | --- |
Mersana Therapeutics Inc | 349.4M | -1.9x | --- |
Cartesian Therapeutics Inc | 368.4M | -0.5x | --- |
TScan Therapeutics Inc | 371.2M | -3.0x | --- |
Foghorn Therapeutics Inc. | 221.8M | -2.2x | --- |
Metagenomi Inc | 252.9M | -3.7x | --- |
Company Information
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Contact Information
- Headquarters
- 2929 7TH STREET, STE 120BERKELEY, CA, United States 94710
- Phone
- 510-982-6030
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- Andrew Guggenhime
- President, Chief Executive Officer, Co-Founder, Director
- Rachel Haurwitz
- Chief Financial Officer
- Jason O'byrne
- Chief People Officer
- Reigin Zawadzki
- Chief Technology Officer
- Tim Kelly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $347.7M |
|---|---|
Revenue (TTM) | $34.5M |
Shares Outstanding | 90.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.45 |
Book Value | $4.17 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | 10.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -336.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
